Aquestive Therapeutics, Inc. (AQST) research
Aquestive Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $4.95
- As of
Aquestive Therapeutics, Inc. (AQST): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-17.
As of . Source: SEC EDGAR filings for AQST. Method and limitations.
Share the AQST intelligence card
See AQST live in the terminal
Track AQST's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live AQST terminal, freeActive signals for AQST
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +229% to AQST (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 52% of AQST (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +107% to AQST (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +229% to AQST (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 52% of AQST (2026Q2)
FREE, NO ACCOUNT
Every signal on AQST, as it fires
You are seeing 5 of 18 signals recorded on AQST since 2026-06-10.
The five above all landed on 2026-09-06. The other 13 were recorded on 3 other days. 14 of the 18 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AQST (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 03843E104 · 2026Q2 | $5.3M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 03843E104 · 2026Q2 | $1.9M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 03843E104 · 2026Q2 | $1.7M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 03843E104 · 2026Q2 | $157K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AQST
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
AQST against its peers
AQST's operating margin of -159.5% ranks in the 3rd percentile of 18 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-05-31.
| Metric | AQST | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 44.5M USD | 269M USD | 8 | 17 |
| Gross margin | n/a | 48.9% | n/a | 15 |
| Operating margin | -159.5% | -2.7% | 3 | 18 |
| Net margin | -188.1% | -15.3% | 3 | 18 |
| Return on equity | n/a | -22.2% | n/a | 17 |
Peers (20): VREOF, TLRY, EOLS, KMDA, TKNO, NIKA, VRNO, CGC, CRLBF, ELTP, CRON, HROW, AKBA, CRDL, TSNDF, GTBIF, ETON, DERM, PRGO, ALVO. Left out: EVO (period gap), BORAY (no annual filing), PHBI (period gap), LFCR (no annual filing), OGI (period gap). Fiscal periods ending between 2025-12-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (AQST: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more AQST signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to AQSTand get the insider, 13F, options, and confluence read in one view.